PHASEBIO PHARMACEUTICALS INC (PHAS) Stock Analyst Ratings
NASDAQ:PHAS - Nasdaq - US7172241090 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 46% to PHAS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 1.02. This target is 1355.06% above the current price.
PHAS was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about PHAS.
In the last month the buy percentage fell by 30 points. So the trust of analysts is decreasing.
PHAS was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-10-24 | Cowen & Co. | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | William Blair | Downgrade | Outperform -> Market Perform |
| 2022-09-28 | Needham | Downgrade | Buy -> Hold |
| 2022-08-15 | Needham | Maintains | Buy |
| 2021-06-17 | Needham | Maintains | Buy |
| 2021-03-16 | Needham | Maintains | Buy |